- treatments for bladder pain and eczema
Description
Aquinox Pharmaceuticals is a clinical stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox Pharmaceuticals (Canada) Inc. is a wholly owned subsidiary of the Company. The primary focus of the Company is anti-inflammatory product candidates targeting SHIP1, which is a regulator of a cellular signaling pathway in immune cells, known as the PI3K pathway. Its lead product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company has completed multiple preclinical studies and clinical trials with AQX-1125, it is advancing through Phase II development in several initial indications. The Company operates in Vancouver, British Columbia, Canada.
Address
Suite 450, 887 Great Northern Way
VANCOUVER, BC V5T 4T5
Canada
VANCOUVER, BC V5T 4T5
Canada
Website
http://www.aqxpharma.comKey stats and ratios
| Q1 (Mar '15) | 2014 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -67.19% | -84.20% |
| Return on average equity | -77.67% | - |
| Employees | 24 |
No comments:
Post a Comment